Pelargonium Sidoides vs Tirzepatide

Q: Is Pelargonium Sidoides better than Tirzepatide?

Tirzepatide has a higher evidence score (7.8/10 vs 6.5/10) and wins in 2 of 3 categories.

Q: Can I take Pelargonium Sidoides and Tirzepatide together?

No documented interaction was found in the data searched. This does not establish that this exact combination is safe.

Head-to-head evidence comparison — which supplement is right for you?

Quick answerNo interaction data — ask a pharmacist

Pelargonium Sidoides vs Tirzepatide: Tirzepatide has the stronger overall evidence (7.8 vs 6.5/10); the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.

Tirzepatide Edges Ahead

Tirzepatide wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.

Pelargonium Sidoides1 win

Tirzepatide2 wins

Which is right for you? Take the 60-second quiz Open in the full comparison tool

Pel6.5

Pelargonium Sidoides

Too few graded studiesModerate safety

Tir7.8

Tirzepatide

Too few graded studiesLimited safety

Evidence

Evidence Score

6.5/10

Studies: 35

Meta-analyses: 2

Level: Moderate

Evidence Score

Best7.8/10

Studies: 133

Meta-analyses: 42

Level: Strong

Research findings

Verdict

Too few graded studies

Top outcomes

Immune supportToo few graded studies5
Safety profileToo few graded studies1

Verdict

Too few graded studies

Top outcomes

Weight managementToo few graded studies80
Glycemic & metabolic controlToo few graded studies53
Heart & blood pressureToo few graded studies20

Dosage & timing

Recommended Dosage:

Liquid EPs 7630: 30 drops three times daily for adults during an acute infection (the cited trials used this dose in 12 to 18 year olds, and gave adults 30, 60 or 90 mg of EPs 7630 a day as tablets)

Warnings

Evidence quality for efficacy is low to very low per the Cochrane review
Rare reports of hepatotoxicity have prompted regulatory cautions
Adverse events (mostly GI) were more frequent than placebo in trials

Best Time:

Spread through the day

Can take on empty stomach

Best Form:

Liquid extract (EPs 7630)

Recommended Dosage:

Once-weekly subcutaneous injection, started at 2.5 mg and escalated by 2.5 mg every 4 weeks to a maintenance dose of 5, 10, or 15 mg (per the prescribing physician and approved indication)

Warnings

PRESCRIPTION DRUG — this is an FDA-approved medication (Mounjaro / Zepbound), not a dietary supplement. Use only under medical supervision for an approved indication.
US FDA labeling includes a boxed warning about thyroid C-cell tumors: tirzepatide caused these tumors in rodents; relevance to humans is uncertain. Under the US label it is contraindicated with a personal or family history of medullary thyroid carcinoma (MTC) or MEN2. For treatment in Germany or Austria, consult the current EU product information for the exact medicine’s locally approved indications, contraindications and warnings; discuss any thyroid history with the prescriber.
Pancreatitis has been reported — discontinue and seek care for severe, persistent abdominal pain; avoid in those with a pancreatitis history.
Gallbladder disease (gallstones, cholecystitis) can occur, partly related to rapid weight loss.
Gastrointestinal adverse effects (nausea, vomiting, diarrhea, constipation) are common, especially during dose escalation.
A portion of the weight lost is lean (muscle) mass — prioritize adequate protein and resistance exercise.
FDA has warned about compounded and grey-market tirzepatide of unverified identity, purity, and dose — do not source outside a legitimate prescription.
Not for cosmetic or off-label use without a medical indication and supervision.
May reduce the efficacy of oral contraceptives via delayed gastric emptying — use a backup method when starting and after dose increases.
Benefits depend on continued use — randomized withdrawal data show substantial weight regain after stopping.

Best Time:

Any time of day

Can take on empty stomach

Best Form:

Once-weekly subcutaneous injection (Mounjaro / Zepbound)

Safety

Moderate safetyBest

Drug Interactions:

Anticoagulants / antiplatelets (e.g. warfarin) (moderate)

Side Effects:

Mild GI upset (nausea, diarrhea, stomach pain)Allergic skin reactionsRare hepatotoxicity (case reports)

Contraindications:

Known liver disease (rare hepatotoxicity reports)
Bleeding disorders or anticoagulant use (theoretical)

Limited safety

Drug Interactions:

Oral contraceptives (moderate)
Insulin and sulfonylureas (moderate)
Oral medications generally (moderate)

Side Effects:

NauseaDiarrheaVomiting

Contraindications:

Personal or family history of medullary thyroid carcinoma (MTC) (a contraindication under the US label)
Multiple endocrine neoplasia syndrome type 2 (MEN2) (a contraindication under the US label)

What you'll notice

🫁 Faster acute-bronchitis recoverypositive

Days 4-7 of an acute episode

🤧 Reduced cold / URTI symptom durationpositive

Within the acute illness window

⚠️ More adverse events than placebonegative

During use

🩸 Strong glycemic controlpositive

Weeks to months

⚖️ Large weight losspositive

Months (dose-escalated over ~20 weeks)

😴 Reduced sleep-apnea severitypositive

Weeks to months

🤢 GI side effects (common)negative

Mostly during titration

Key studies

Pelargonium sidoides extract for treating acute respiratory tract infections.

Cochrane Database Syst Rev (2013) · Systematic review · n=10 trials; ~746 adults and ~819 children

Liquid EPs 7630 showed effectiveness for acute bronchitis in both adults and children; tablets did not

Treatment of acute bronchitis with EPs 7630: randomized, controlled trial in children and adolescents.

Pediatr Int (2012) · Rct · n=220 children/adolescents

Significantly greater BSS reduction with EPs 7630 versus placebo (P<0.0001)

Efficacy and tolerability of EPs 7630 tablets in patients with acute bronchitis: a randomised, double-blind, placebo-controlled dose-finding study with a herbal drug preparation from Pelargonium sidoides.

Wien Med Wochenschr (2010) · Rct · n=406 adults

All three active dose groups improved patient-reported outcomes versus placebo at day 7

All Pelargonium Sidoides studies

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.

N Engl J Med (2021) · Rct · n=1879

Open-label 40-week phase-3 head-to-head RCT (SURPASS-2) in 1879 patients with type 2 diabetes, tirzepatide 5/10/15 mg vs semaglutide 1 mg

Tirzepatide Once Weekly for the Treatment of Obesity.

N Engl J Med (2022) · Rct · n=2539

72-week phase-3 double-blind RCT (SURMOUNT-1) in 2539 adults with obesity (without diabetes), tirzepatide 5/10/15 mg vs placebo

Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.

N Engl J Med (2025) · Rct · n=751

Phase-3b open-label head-to-head RCT (SURMOUNT-5) in 751 adults with obesity but without diabetes, max-tolerated tirzepatide vs max-tolerated semaglutide

All Tirzepatide studies

Frequently asked questions

Is Pelargonium Sidoides better than Tirzepatide?

Tirzepatide has a higher evidence score (7.8/10 vs 6.5/10) and wins in 2 of 3 categories.

Can I take Pelargonium Sidoides and Tirzepatide together?

No documented interaction was found in the data searched. This does not establish that this exact combination is safe.

Related comparisons

Liraglutide vs Pelargonium Sidoides Pelargonium Sidoides vs Thiamine Pelargonium Sidoides vs Vitamin B12 Semaglutide vs Tirzepatide Liraglutide vs Tirzepatide Thiamine vs Tirzepatide

Still deciding between Pelargonium Sidoides and Tirzepatide?

The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.

Get your personalised pick Pelargonium Sidoides details Tirzepatide details

Warnings

PRESCRIPTION DRUG — this is an FDA-approved medication (Mounjaro / Zepbound), not a dietary supplement. Use only under medical supervision for an approved indication.

US FDA labeling includes a boxed warning about thyroid C-cell tumors: tirzepatide caused these tumors in rodents; relevance to humans is uncertain. Under the US label it is contraindicated with a personal or family history of medullary thyroid carcinoma (MTC) or MEN2. For treatment in Germany or Austria, consult the current EU product information for the exact medicine’s locally approved indications, contraindications and warnings; discuss any thyroid history with the prescriber.

Pancreatitis has been reported — discontinue and seek care for severe, persistent abdominal pain; avoid in those with a pancreatitis history.

Gallbladder disease (gallstones, cholecystitis) can occur, partly related to rapid weight loss.

Gastrointestinal adverse effects (nausea, vomiting, diarrhea, constipation) are common, especially during dose escalation.

A portion of the weight lost is lean (muscle) mass — prioritize adequate protein and resistance exercise.

FDA has warned about compounded and grey-market tirzepatide of unverified identity, purity, and dose — do not source outside a legitimate prescription.

Not for cosmetic or off-label use without a medical indication and supervision.

May reduce the efficacy of oral contraceptives via delayed gastric emptying — use a backup method when starting and after dose increases.

Benefits depend on continued use — randomized withdrawal data show substantial weight regain after stopping.

Frequently asked questions

Is Pelargonium Sidoides better than Tirzepatide?

Tirzepatide has a higher evidence score (7.8/10 vs 6.5/10) and wins in 2 of 3 categories.

Can I take Pelargonium Sidoides and Tirzepatide together?

No documented interaction was found in the data searched. This does not establish that this exact combination is safe.